Literature DB >> 19887137

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.

M Knuf1, D Kieninger-Baum, P Habermehl, P Muttonen, H Maurer, P Vink, J Poolman, D Boutriau.   

Abstract

Meningococcal disease incidence is highest in young children, yet a tetravalent conjugate vaccine is currently not available for this age group. This study evaluated a single dose of four different ACWY-TT conjugate vaccine formulations in 240 toddlers (12-14 months) and 268 children (3-5 years) compared to licensed age-appropriate control vaccines. In toddlers, rSBA-MenC GMTs for the selected formulation were statistically higher than after monovalent-MenC-conjugate vaccine. In children, rSBA-GMTs against each serogroup were statistically higher than after tetravalent polysaccharide vaccine. The safety profile was comparable to licensed controls. The new ACWY-TT conjugate vaccine promises high seroprotection levels against meningococcal disease from 1 year of age.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19887137     DOI： 10.1016/j.vaccine.2009.10.064

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  23 in total

Review 1.  Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence.

Authors:  Aia Assaf-Casals; Ghassan Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

2.  The 26th International Pediatric Association Congress of Pediatrics, Johannesburg, South Africa, 4-9 August 2010.

Authors:  Michelle I Wilde
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

Review 3.  Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).

Authors:  Jamie D Croxtall; Sohita Dhillon
Journal:  Drugs       Date:  2012-12-24       Impact factor: 9.546

4.  Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.

Authors:  Socorro Lupisan; Kriengsak Limkittikul; Nestor Sosa; Pornthep Chanthavanich; Véronique Bianco; Yaela Baine; Marie Van der Wielen; Jacqueline M Miller
Journal:  Clin Vaccine Immunol       Date:  2013-07-24

Review 5.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

6.  Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay.

Authors:  Jan T Poolman; Isabel De Vleeschauwer; Nathalie Durant; Nathalie Devos; Christiane Feron; Pascal Lestrate; Vincent Weynants; Dominique Boutriau
Journal:  Clin Vaccine Immunol       Date:  2011-05-18

7.  Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines.

Authors:  Lidia Serra; Markus Knuf; Federico Martinón-Torres; Kevin Yi; Jamie Findlow
Journal:  Hum Vaccin Immunother       Date:  2021-02-19       Impact factor: 3.452

8.  The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults.

Authors:  Mari Rose Aplasca-De Los Reyes; Efren Dimaano; Noel Macalalad; Ghassan Dbaibo; Veronique Bianco; Yaela Baine; Jacqueline Miller
Journal:  Hum Vaccin Immunother       Date:  2012-04-09       Impact factor: 3.452

9.  The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study.

Authors:  Ghassan Dbaibo; Noel Macalalad; Mari Rose Aplasca-De Los Reyes; Efren Dimaano; Veronique Bianco; Yaela Baine; Jacqueline Miller
Journal:  Hum Vaccin Immunother       Date:  2012-04-09       Impact factor: 3.452

10.  Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.

Authors:  Charissa Borja-Tabora; Cecilia Montalban; Ziad A Memish; Marie Van der Wielen; Veronique Bianco; Dominique Boutriau; Jacqueline Miller
Journal:  BMC Infect Dis       Date:  2013-03-05       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.